Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
ArQule
ClinicalTrials.gov Identifier:
NCT01395758
First received: July 1, 2011
Last updated: January 7, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2016
  Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)